News for Palatin Technologies, Inc. - Google Finance

Faruqi & Faruqi, LLP Launches An Investigation Against Palatin Technologies ...

Tue, 04 Jun 2013 23:01:22 GMT

Faruqi & Faruqi, LLP Launches An Investigation Against Palatin Technologies ...
Business Wire (press release) - Jun 4, 2013

NEW YORK--(BUSINESS WIRE)--Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Palatin Technologies Inc. (“Palatin” or the “Company”) (NYSE ...

Palatin Technologies, Inc. (NYSEMKT:PTN) Long Term Investor Investigation ...

Tue, 11 Jun 2013 12:30:42 GMT

Palatin Technologies, Inc. (NYSEMKT:PTN) Long Term Investor Investigation ...
SBWire (press release) - Jun 11, 2013

An investigation for current long-term investors in shares of Palatin Technologies, Inc. (NYSEMKT:PTN) over potential wrongdoing by certain officers and directors of Palatin Technologies was announced and current long-term NYSE:PTN stockholders should ...

"Palatin Technologies, Inc. - Product Pipeline Review - 2013" Published

Fri, 24 May 2013 17:21:47 GMT

"Palatin Technologies, Inc. - Product Pipeline Review - 2013" Published
SBWire (press release) - May 24, 2013

Boston, MA -- (SBWIRE) -- 05/24/2013 -- Global Market Direct's pharmaceuticals report, "Palatin Technologies, Inc. - Product Pipeline Review - 2013" provides data on the Palatin Technologies, Inc.'s research and development focus. The report includes ...

Despite Confusion, Palatin's Phase II Data Solid

Sat, 15 Jun 2013 03:35:53 GMT

Despite Confusion, Palatin's Phase II Data Solid
Seeking Alpha - Jun 15, 2013

Palatin Technologies Inc. is a development stage biopharmaceutical company that is planning to start screening patients for Phase III trials later this year with its drug candidate bremelanotide for the treatment of FSD.

Sex Improves With Vaginal Atrophy Treatment, Survey Finds

Mon, 10 Jun 2013 21:18:54 GMT

Sex Improves With Vaginal Atrophy Treatment, Survey Finds
Medscape - Jun 10, 2013

... Sprout Pharmaceuticals, Teva Pharmaceutical Industries Ltd, Warner Chilcott, and Watson Pharmaceutical Inc; has received or is currently receiving grant/research support from BioSante, EndoCeutics Inc, Novo Nordisk, Novogyne, Palatin Technologies, ...

Self-Administered Injection Boosts Low Sex Drive in Women

Thu, 30 May 2013 19:36:36 GMT

Self-Administered Injection Boosts Low Sex Drive in Women
Medscape - May 30, 2013

This study was funded by Palatin Technologies Inc. Dr. Clayton reports financial relationships with Palatin Technologies Inc., Ballantine Books/Random House, Changes in Sexual Functioning Questionnaire, Guilford Publications, BioSante Pharmaceuticals, ...

Recent Insider Buying Just One More Reason To Consider Vivus

Mon, 03 Jun 2013 20:07:00 GMT

Recent Insider Buying Just One More Reason To Consider Vivus
Seeking Alpha - Jun 3, 2013

Vivus, Inc., (VVUS) shares were trading around $25 in late 2012 and even higher before that. However, the stock has since headed lower as seemingly impatient investors sold shares.

Faruqi & Faruqi, LLP Launches An Investigation Against Palatin Technologies Inc For Potential Breaches Of Fiduciary Duties By Board Of Directors

Tue, 04 Jun 2013 23:00:00 GMT

Faruqi & Faruqi, LLP Launches An Investigation Against Palatin Technologies Inc For Potential Breaches Of Fiduciary Duties By Board Of Directors
Reuters Key Development - Jun 4, 2013

Palatin Technologies Inc Announces Pricing Of $35 Million Private Placement Of Common Stock And Warrants

Mon, 02 Jul 2012 20:30:00 GMT

Palatin Technologies Inc Announces Pricing Of $35 Million Private Placement Of Common Stock And Warrants
Reuters Key Development - Jul 2, 2012

Palatin Technologies Inc Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca PLC Research Collaboration

Tue, 19 Jun 2012 11:30:00 GMT

Palatin Technologies Inc Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca PLC Research Collaboration
Reuters Key Development - Jun 19, 2012